Metagenomi, INC 10-Q quarterly reports

Metagenomi Therapeutics, Inc. filed its quarterly report for the period ending June 30, 2026, detailing ongoing research and development efforts, financial performance, and risk factors.

Metagenomi Therapeutics, Inc. reported a net loss of $23.1 million for the first quarter of 2026, with a decrease in collaboration revenue and operating expenses.

Metagenomi, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, driven by terminated collaboration agreements, while announcing a new CEO and positive preclinical data for its lead hemophilia A program.

Metagenomi, a precision genetic medicines company, reported a significantly wider net loss in the second quarter of 2025 due to a substantial decrease in collaboration revenue, primarily from the termination of its agreement with Moderna, despite progress in its genome editing pipeline.

Metagenomi, a precision gene editing company, announces its Q1 2025 financial results, highlighting progress in its research and development programs and collaborations.

Metagenomi's Q3 2024 report details financial results, pipeline advancements, and strategic shifts, including the termination of the Moderna collaboration and progress in hemophilia A and cardiometabolic programs.

Metagenomi, a precision genetic medicines company, released its second quarter 2024 results, highlighting progress in its therapeutic programs and platform technology.

Metagenomi's first quarter 2024 results show increased collaboration revenue and R&D spending, alongside the termination of the Moderna agreement and progress in key therapeutic programs.